vBloc(R) Neurometabolic therapy demonstrates 34% excess weight loss in ReCharge study
EnteroMedics announced that analyses of the ReCharge Study demonstrated Excess Weight Loss of 34% and significant improvements in obesity-related risk factors for vBloc® Therapy treated, moderately obese patients who had at least one comorbidity. September 01, 2015